Study of the 2.25mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions

Completed · Phase 3

Conditions studied: Coronary Artery Disease

In brief

The main objective of this study is to assess the safety and effectiveness of the sirolimus-eluting Bx VELOCITYTM stent in reducing in-lesion restenosis in patients with de novo native coronary artery lesions.

Key facts

Study ID

NCT00232739

Run by

Cordis US Corp.

People needed

100

Starts

2003-09-01

Expected to finish

2009-08-01

Last updated by the study team

2010-03-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or non-pregnant female patients minimum 18 years of age
• Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B\&C, I-II) OR patients with documented silent ischemia;
• Target lesion is 20mm in length (visual estimate);
• Target lesion stenosis is >50% and <100% (visual estimate);

You may not qualify if…

• Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK >2 times normal within the preceding 24 hours and the CK and CK-MB enzymes remains above normal at the time of treatment;
• Has unstable angina classified as Braunwald III B or C, or is having a peri infarction;
• Documented Left ventricular ejection fraction 25%;
• Impaired renal function (creatinine > 3.0 mg/dl) at the time of treatment;

Where it is running

• Lenox Hill Hospital — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.